摘要
最新研究结果提示,给予标准治疗的同时阻滞醛固酮受体,可减少患有如糖尿病肾病、慢性肾病患者的蛋白尿,对器官损伤有潜在保护作用,使得新型醛固酮受体拮抗剂研究成为热点。本文主要介绍第三代醛固酮受体拮抗剂——fi nerenone,该药对心力衰竭具有良好的疗效,对肾脏具有重要的保护作用,且性激素相关不良反应少。
Evidence suggests that mineralocorticoid receptor blockade, when given in combination with standard therapy, reduces proteinuria in patients with renal disorders, such as diabetic nephropathy and chronic kidney diseases, indicating a potentially huge unmet medical need. This article focuses on recent advances in finerenone, the third generation mineralocorticoid receptor（MR） antagonists. Several clinical trials show that the drug has a good therapeutic effect on heart failure and plays an important role in kidney protection with few sex hormone-related adverse reactions.
出处
《中南药学》
CAS
2015年第11期1190-1194,共5页
Central South Pharmacy
